0001209191-20-020483.txt : 20200320 0001209191-20-020483.hdr.sgml : 20200320 20200320170012 ACCESSION NUMBER: 0001209191-20-020483 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200319 FILED AS OF DATE: 20200320 DATE AS OF CHANGE: 20200320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DILLY STEPHEN GEORGE CENTRAL INDEX KEY: 0001389147 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 20732665 MAIL ADDRESS: STREET 1: C/O AVIGEN, INC. STREET 2: 1301 HARBOR BAY PKWY CITY: ALAMEDA STATE: CA ZIP: 94502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-19 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001389147 DILLY STEPHEN GEORGE C/O SANGAMO THERAPEAUTICS, INC. 7000 MARINA BLVD. BRISBANE CA 94005 1 0 0 0 Common Stock 2020-03-19 4 M 0 35000 5.42 A 40000 D Common Stock 2020-03-19 4 S 0 35000 6.00 D 5000 D Stock Option (Right-to-Buy) 5.42 2020-03-19 4 M 0 35000 0.00 D 2020-03-30 Common Stock 35000 0 D Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 15, 2019. The price reported is a weighted average price. The shares were sold at prices ranging from $6.00 to $6.02 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. The option was immediately exercisable for all option shares, but shares purchased under the option were subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vested in monthly installments upon completion of each month of Board service over a three year period measured from the date of grant. /s/ Matthew Colvin, Attorney-in-Fact for Stephen G. Dilly 2020-03-20